ArticlePsychopharmacology2026
Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleScopolamine, whose rapid and sustained antidepressant effects were first described nearly two decades ago, is associated with significant adverse effects that limit its clinical use. A safer alternative may involve coadministration of scopolamine at lower doses with other compounds that exhibit antidepressant properties. Growing evidence highlights the potential of group II metabotropic glutamate (mGlu) receptors as targets for depression treatment.
objectivesThis study aimed to evaluate whether the mGlu2 receptor NAM, VU6001966, can enhance the antidepressant-like effects of a subeffective dose of scopolamine in a mouse model of depression and to explore the underlying mechanism.
methodsUnpredictable chronic mild stress (UCMS) was employed as an animal model of depression. Behavioral tests assessing anhedonia-, apathy-, and helplessness-like states were used to evaluate the effects of a four-day coadministration of scopolamine and VU6001966. The impact of the drug combination on spatial and non-spatial learning was assessed in both naïve and stressed mice. Protein expression levels in the prefrontal cortex (PFC) and hippocampus were measured via Western blotting. Electrophysiological recordings in the medial PFC (mPFC) were conducted to assess excitatory synaptic transmission and long-term potentiation (LTP).
resultsSubchronic VU6001966 treatment dose-dependently alleviated stress-induced depressive-like behaviors in mice. Moreover, a subeffective dose of VU6001966 potentiated the effects of a subeffective dose of scopolamine, significantly reducing UCMS-induced apathy- and anhedonia-like behaviors. Behavioral effects of the AMPA receptor antagonist NBQX and the TrkB receptor antagonist ANA-12 suggest that both AMPA and TrkB receptors contribute to the antidepressant-like actions of scopolamine combined with VU6001966. Consistent with these findings, Western blot analysis revealed accompanying changes in the pTrkB/TrkB ratio in the PFC. The combination of scopolamine and VU6001966 did not impair cognitive function or locomotor activity. However, electrophysiological recordings did not reveal any improvement in UCMS-induced impairments in excitatory synaptic transmission or LTP in the mPFC.
conclusionsCoadministration of scopolamine with the mGlu2 NAM VU6001966 may offer a promising therapeutic strategy for the treatment of depression. Further studies are needed to clarify the underlying mechanisms and confirm its efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.